145 related articles for article (PubMed ID: 25732374)
1. Reply to: Colon LB, Perissinotti A, Santarosa M, Marini BL. Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy.
Pediatr Blood Cancer; 2015 Jun; 62(6):1116. PubMed ID: 25732374
[No Abstract] [Full Text] [Related]
2. Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy.
Benitez L; Perissinotti AJ; Santarossa M; Marini BL
Pediatr Blood Cancer; 2015 Jun; 62(6):1115. PubMed ID: 25649118
[No Abstract] [Full Text] [Related]
3. Clinical application of asparaginase activity levels following treatment with pegaspargase.
Bleyer A; Asselin BL; Koontz SE; Hunger SP
Pediatr Blood Cancer; 2015 Jun; 62(6):1102-5. PubMed ID: 25393506
[TBL] [Abstract][Full Text] [Related]
4. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
[TBL] [Abstract][Full Text] [Related]
5. Pegaspargase for acute lymphoblastic leukemia.
Med Lett Drugs Ther; 1995 Mar; 37(944):23-4. PubMed ID: 7877556
[No Abstract] [Full Text] [Related]
6. PEG-linked asparaginase marketed.
Am J Hosp Pharm; 1994 Jun; 51(11):1382. PubMed ID: 7942872
[No Abstract] [Full Text] [Related]
7. Clinical decisions following implementation of asparaginase activity monitoring in pediatric patients with acute lymphoblastic leukemia: Experience from a single-center study.
Nadeem K; Colantonio D; Kircanski I; Naqvi A; Hitzler J; Whitlock JA; Dupuis LL
Pediatr Blood Cancer; 2020 Feb; 67(2):e28044. PubMed ID: 31625674
[TBL] [Abstract][Full Text] [Related]
8. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962).
Kurre HA; Ettinger AG; Veenstra DL; Gaynon PS; Franklin J; Sencer SF; Reaman GH; Lange BJ; Holcenberg JS
J Pediatr Hematol Oncol; 2002; 24(3):175-81. PubMed ID: 11990302
[TBL] [Abstract][Full Text] [Related]
9. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
10. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4
Schore RJ; Devidas M; Bleyer A; Reaman GH; Winick N; Loh ML; Raetz EA; Carroll WL; Hunger SP; Angiolillo AL
Leuk Lymphoma; 2019 Jul; 60(7):1740-1748. PubMed ID: 30626253
[TBL] [Abstract][Full Text] [Related]
11. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment.
Peters BG; Goeckner BJ; Ponzillo JJ; Velasquez WS; Wilson AL
Formulary; 1995 Jul; 30(7):388-93. PubMed ID: 10151730
[TBL] [Abstract][Full Text] [Related]
12. Pegaspargase: a review of clinical studies.
Graham ML
Adv Drug Deliv Rev; 2003 Sep; 55(10):1293-302. PubMed ID: 14499708
[TBL] [Abstract][Full Text] [Related]
13. [Advances on the role of pegaspargase in the treatment of childhood leukemia].
Liu L; Xie XT
Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):155-60. PubMed ID: 24568909
[TBL] [Abstract][Full Text] [Related]
14. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia.
Lau KM; Saunders IM; Goodman A
J Oncol Pharm Pract; 2020 Jan; 26(1):193-199. PubMed ID: 30823860
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393
[TBL] [Abstract][Full Text] [Related]
16. Pegaspargase.
Alfieri DR
Pediatr Nurs; 1995; 21(5):471-4, 490. PubMed ID: 8684851
[TBL] [Abstract][Full Text] [Related]
17. L-asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia.
Rathi B; Azad RK; Vasudha N; Hissaria P; Sawlani V; Gupta RK
Pediatr Neurosurg; 2002 Oct; 37(4):203-5. PubMed ID: 12372914
[TBL] [Abstract][Full Text] [Related]
18. Peg-asparaginase for acute lymphoblastic leukemia.
Rytting M
Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
[TBL] [Abstract][Full Text] [Related]
19. Development of a Lyophilized Formulation of Pegaspargase and Comparability Versus Liquid Pegaspargase.
Faschinger AM; Sessler N
Adv Ther; 2019 Aug; 36(8):2106-2121. PubMed ID: 31140125
[TBL] [Abstract][Full Text] [Related]
20. Asparaginase activity monitoring experience from the Maritimes, Canada.
Pike M; Kulkarni K; MacDonald T
Leuk Lymphoma; 2019 Sep; 60(9):2312-2315. PubMed ID: 30721104
[No Abstract] [Full Text] [Related]
[Next] [New Search]
